Impact of interruption of CFTR modulator therapies
Journal of Cystic Fibrosis · 2024
DOI: 10.1016/j.jcf.2024.05.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2024. Verfasst von Burcu Capraz Yavuz und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatric Pulmonology, Hacettepe University Faculty of Medicine, Ihsan Dogramaci Children's Hospital, Ankara, Türkiye. Electronic addr…. Hauptthemen laut MEDLINE: Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 14 Literaturangaben.
Abstract (Originalsprache)
Novel drug therapy targeting the defective cystic fibrosis transmembrane conductance regulator protein has the potential to significantly enhance the quality of life for numerous patients with cystic fibrosis. However, in some countries social insurance does not pay for modulators because these drugs are extremely expensive. This study sought to understand the impact on the health of children whose modulator treatments were interrupted because of legal procedures and delivery processes. Our study identified that the significant increase in percent-predicted forced expiratory volume levels (FEV1) and BMI z-score values associated with modulator therapies decreased sharply with their discontinuation. Significant worsening in FEV1, BMI z-scores, and BW z-scores were detected in the first follow-up visit after therapy discontinuation within 1 month. Eight patients had a reduction of FEV1 of more than 10%. The findings suggest that modulatory treatment continuation is important, and it is crucial that treatment is not interrupted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Paediatric Pulmonology, Hacettepe University Faculty of Medicine, Ihsan Dogramaci Children's Hospital, Ankara, Türkiye. Electronic address: burcucapraz@hacettepe.edu.tr.
- Department of Paediatric Pulmonology, Hacettepe University Faculty of Medicine, Ihsan Dogramaci Children's Hospital, Ankara, Türkiye.
Zitieren
APA
Capraz Yavuz, B., Yalcin, E., Nayir Buyuksahin, H., Sunman, B., Guzelkas, I., Alboga, D., Akgul Erdal, M., Demir, H. I., Atan, R., Emiralioglu, N., Dogru, D., Ozcelik, U., & Kiper, N. (2024). Impact of interruption of CFTR modulator therapies. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2024.05.006
Vancouver
Capraz Yavuz B, Yalcin E, Nayir Buyuksahin H, Sunman B, Guzelkas I, Alboga D, et al. Impact of interruption of CFTR modulator therapies. Journal of Cystic Fibrosis. 2024. doi:10.1016/j.jcf.2024.05.006
BibTeX
@article{CaprazYavuz2024,
author = {Capraz Yavuz, Burcu and Yalcin, Ebru and Nayir Buyuksahin, Halime and Sunman, Birce and Guzelkas, Ismail and Alboga, Didem and Akgul Erdal, Meltem and Demir, Havva Ipek and Atan, Raziye and Emiralioglu, Nagehan and Dogru, Deniz and Ozcelik, Ugur and Kiper, Nural},
title = {Impact of interruption of CFTR modulator therapies},
journal = {Journal of Cystic Fibrosis},
year = {2024},
doi = {10.1016/j.jcf.2024.05.006}
}
EUVIMED